What is Leerink Partnrs' Estimate for PTGX Q3 Earnings?

Key Points

• Leerink Partners estimates Protagonist Therapeutics will report Q3 2025 earnings per share of ($0.60), with a full-year expectation of ($1.95) EPS.
• The stock currently has a consensus "Buy" rating, with price targets ranging from $67.00 to $80.00 among various analysts.
• Insider transactions revealed significant stock sales, with CEO Dinesh V. Patel selling 10,415 shares and Director William D. Waddill selling 4,000 shares recently.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at Leerink Partnrs issued their Q3 2025 earnings estimates for Protagonist Therapeutics in a note issued to investors on Friday, September 12th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($0.60) for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. Leerink Partnrs also issued estimates for Protagonist Therapeutics' Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS.

PTGX has been the topic of a number of other reports. Leerink Partners assumed coverage on Protagonist Therapeutics in a research note on Friday. They issued an "outperform" rating and a $73.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Citigroup reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a report on Thursday, August 7th. Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Finally, JMP Securities raised their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a report on Thursday, August 7th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $67.73.

Protagonist Therapeutics Stock Down 1.4%

Shares of PTGX stock opened at $58.86 on Monday. Protagonist Therapeutics has a fifty-two week low of $33.31 and a fifty-two week high of $61.89. The stock has a market capitalization of $3.66 billion, a P/E ratio of 84.09 and a beta of 2.22. The stock has a 50-day simple moving average of $55.70 and a 200 day simple moving average of $50.87.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The firm had revenue of $5.55 million during the quarter, compared to analyst estimates of $8.32 million.

Insiders Place Their Bets

In other news, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total transaction of $237,000.00. Following the completion of the transaction, the director directly owned 9,130 shares of the company's stock, valued at $540,952.50. This represents a 30.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $54.78, for a total value of $570,533.70. Following the sale, the chief executive officer owned 520,603 shares in the company, valued at $28,518,632.34. The trade was a 1.96% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,859 shares of company stock valued at $3,687,577. 4.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of large investors have recently modified their holdings of PTGX. GF Fund Management CO. LTD. raised its position in Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company's stock worth $74,000 after purchasing an additional 275 shares during the last quarter. Guggenheim Capital LLC boosted its stake in shares of Protagonist Therapeutics by 1.6% in the 2nd quarter. Guggenheim Capital LLC now owns 19,208 shares of the company's stock worth $1,062,000 after buying an additional 303 shares during the last quarter. Bessemer Group Inc. grew its stake in Protagonist Therapeutics by 171.0% in the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company's stock valued at $28,000 after buying an additional 318 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Protagonist Therapeutics by 4.1% in the 1st quarter. Hsbc Holdings PLC now owns 8,458 shares of the company's stock worth $405,000 after purchasing an additional 330 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Protagonist Therapeutics by 16.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,394 shares of the company's stock worth $132,000 after purchasing an additional 340 shares during the period. Institutional investors and hedge funds own 98.63% of the company's stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.